A new review looks at how a cell process called histone lactylation might connect sugar metabolism to salivary gland damage in Sjogren's disease. Histone lactylation is a way cells attach chemical tags to proteins that package DNA, which can change how genes behave. The review suggests this process may act as a bridge between glycolysis, the way cells break down sugar, and the scarring of salivary glands.
The authors point to three areas where this process may play a role: how immune cells polarize, how epithelial cells change into mesenchymal cells, and how myofibroblasts become activated. These are all processes tied to tissue scarring and inflammation.
The review does not report a study population, sample size, or follow-up. It also does not report safety data, adverse events, or tolerability. The main limitation is that direct evidence in Sjogren's disease is currently lacking. The authors drew on findings from other fields, including immunometabolism, epigenetic rewiring, and tissue fibrogenesis.
The takeaway is that histone lactylation is a potential area for future biomarkers and treatments, not a proven cause or a current therapy. People with Sjogren's disease should talk with their doctor about any treatment decisions.
Common questions
What is histone lactylation?
Histone lactylation is a process where cells attach chemical tags to proteins that package DNA. This can change how genes are turned on or off. The review suggests it may connect glycolysis, the breakdown of sugar, to salivary gland scarring in Sjogren's disease. However, the review does not report direct evidence in Sjogren's patients.
Does this mean there is a new treatment for Sjogren's disease?
No. The review only suggests that histone lactylation could be a target for future biomarkers and treatments. It does not report any tested treatment, patient population, or safety data. Any treatment decisions should be discussed with a doctor.
Is this finding based on studies in people with Sjogren's?
No. The review states that direct evidence in Sjogren's disease is currently lacking. The authors synthesized findings from other fields, including immunometabolism, epigenetic rewiring, and tissue fibrogenesis. This means the link is a hypothesis, not a proven cause.
What are the side effects or safety concerns?
The review does not report any adverse events, serious adverse events, discontinuations, or tolerability data. Because no treatment was tested in this review, there are no safety results to share. Anyone considering treatment should speak with their doctor.